Oncology company Nuvation Bio Inc. (NUVB) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved IBTROZI (taletrectinib) for the treatment of adult patients with ROS1-positive (ROS1+) unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC).
As part of an exclusive license agreement entered in 2023, Nippon Kayaku will commercialize IBTROZI in Japan.
The approval by Japan's MHLW was based on data from the pivotal Phase 2 TRUST clinical program evaluating taletrectinib in patients globally, including Japan. Upon the first establishment of the reimbursement price in Japan, which is anticipated in the fourth quarter of 2025, Nuvation Bio will receive a $25 million milestone payment to go towards continued progression of our pipeline and portfolio.
In parallel, the MHLW also approved the AmoyDx PLC Panel as a companion diagnostic to identify patients with locally advanced or metastatic ROS1+ NSCLC who may benefit from treatment with IBTROZI.
IBTROZI is already approved for similar indication by the U.S. Food and Drug Administration (FDA) on June 11, 2025, and by China's National Medical Products Administration (NMPA) on January 6, 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.